nach oben

best practice onkologie

Erschienen in:

02.12.2014 | Topic_Mammakarzinom

Adjuvante endokrine Therapie des Mammakarzinoms — ein Update

verfasst von: Dr. S. Steer, Prof. Dr. D. Lüftner

Erschienen in: best practice onkologie | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Mammakarzinom ist die häufigste maligne Erkrankung der Frau. Jährlich erkranken in Deutschland etwa 70.000 Frauen an einem Mammakarzinom [24]. Durch die adjuvanten Therapien konnte die Mortalität in den letzten Jahren deutlich gesenkt werden [14]. Zu den adjuvanten Therapien zählen in erster Linie die endokrine Therapie bei hormonrezeptorpositivem Mammakarzinom sowie die Chemotherapie bei höherem Rezidivrisiko. Allein durch die adjuvante endokrine Therapie konnte das kumulative Sterberisiko über 15 Jahre signifikant um etwa 40 % gesenkt werden.

[1]

AGO Breast Committee (2014) Diagnosis and treatment of patients with primary and metastatic breast cancer. Recommendations. http://www.ago-online.de

[2]

Amir E, Seruga B, Niraula S et al (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 103:1–11CrossRef

[3]

Berndt U, Leplow B, Kantelhardt E et al (2009) Cognitive effects of systemic therapy in patients with breast cancer. Breast Care (Basel) 4:177–182CrossRef

[4]

BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A et al (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361:766–776PubMedCrossRef

[5]

Burstein HJ, Prestrud AA, Seidenfeld J et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784–3796PubMedCrossRef

[6]

Coleman RE, Bolten WW, Lansdown M et al (2008) Aromatase inhibitor induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 34:275–282PubMedCrossRef

[7]

Coombes RC, Kilburn LS, Snowdon CF et al (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561):559–570PubMedCrossRef

[8]

Craig MC, Fletcher PC, Daly EM et al (2008) A study of visuospatial working memory pre- and post-Gonadotropin Hormone Releasing Hormone agonists (GnRHa) in young women. Horm Behav 54:47–59PubMedCrossRef

[9]

Cuzick J, Ambroisine L, LHRH-agonists in Early Breast Cancer Overview group et al (2007) Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormonereceptorpositive breast cancer: a meta-analysis of individual patient data from randomized adjuvant trials. Lancet 369(9574):1711–1723PubMedCrossRef

[10]

Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135–1141PubMedCrossRef

[11]

Davies C, Pan H, Godwin J, Gray R et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor- positive breast cancer: ATLAS, a randomized trial. Lancet 381(9869):805–816PubMedCentralPubMedCrossRef

[12]

Domchek SM, Friebel TM, Neuhausen SL et al (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 7:223–229PubMedCrossRef

[13]

Domchek SM, Friebel TM, Singer CF et al (2010) Association of riskreducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967–975PubMedCentralPubMedCrossRef

[14]

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient level meta-analysis of randomised trials. Lancet 378(9793):771–784PubMedCrossRef

[15]

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717CrossRef

[16]

Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114):1451–1467CrossRef

[17]

Goss PE, Ingle JN, Martino S et al (2009) Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA17 Trial. San Antonio Breast Cancer Symposium (abstract 13)

[18]

Gray RG, Rea D, Handley K et al (2013) aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31 (suppl; abstr 5)

[19]

Hershman DL, Shao T, Kushi LH et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537PubMedCentralPubMedCrossRef

[20]

Higgins MJ, Liedke PE, Goss PE (2013) Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCICCTGMA. 17/BIG 1-97 trial. Crit Rev Oncol Hematol 86:23–32PubMedCrossRef

[21]

Ingle JN (2006) Adjuvant endocrine therapy for postmenopausal women with early breast cancer. Clin Cancer Res 12(3 Pt 2):1031s–1036sPubMedCrossRef

[22]

Jakesz R, Gnant M, Griel R et al (2008) Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8. San Antonio Breast Cancer Symposium (abstract 14)

[23]

Kaufmann M, Jonat W, Hilfrich J et al (2007) Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 25(19):2664–2670PubMedCrossRef

[24]

Krebs in Deutschland 2009/2010. 9. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (Hrsg). Berlin, 2013

[25]

National Comprehensive Cancer Network®. NCCN Guidelines Version3.2013. Invasive Breast Cancer. Definition of Menopause (BINV-L). http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Zugegriffen: 30. Juli 2013

[26]

Ortmann O, Cufer T, Dixon JM et al (2009) Adjuvant endocrine therapy for perimenopausal women with early breast cancer. Breast 18(1):2–7PubMedCrossRef

[27]

Pagani O, Regan MM, Walley B et al (2014) Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): joint analysis of IBCSG TEXT and SOFT trials. J Clin Oncol 32:5s (suppl; abstr LBA1)

[28]

Regan MM, Leyland-Jones B, Bouzyk M et al (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1–98 trial. J Natl Cancer Inst 104(6):441–451PubMedCentralPubMedCrossRef

[29]

Regan MM, Neven P, Giobbie-Hurder A et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1–98 randomised clinical trial at 8•1 years median follow-up. Lancet Oncol 12:1101–1108PubMedCentralPubMedCrossRef

[30]

Smith IE, Dowsett M, Yap YS et al (2006) Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 24:2444–2447PubMedCrossRef

Titel: Adjuvante endokrine Therapie des Mammakarzinoms — ein Update
verfasst von: Dr. S. Steer
Prof. Dr. D. Lüftner
Publikationsdatum: 02.12.2014
Verlag: Springer-Verlag
Erschienen in: best practice onkologie / Ausgabe 6/2014
Print ISSN: 0946-4565
Elektronische ISSN: 1862-8559
DOI: https://doi.org/10.1007/s11654-014-0517-y

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Adjuvante endokrine Therapie des Mammakarzinoms — ein Update

Zusammenfassung

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2014

Malignes Melanom: Kombinationstherapie

Was bringt die Laserblutbehandlung?

Nach einem mutigen Schritt — eine Rolle rückwärts

Nebenwirkungen von Krebsmedikamenten

Filgrastim — Kampf der febrilen Neutropenie

Anamorelin bewirkt Gewichtszunahme und Symptomreduktion

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie